
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11362375/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Focus (American) Tj ETQq1 1 0.78	43140r. g BT /	Overlock 10
2	Sonication of the Anterior Thalamus With MRI-Guided Transcranial Focused Ultrasound (tFUS) Alters Pain Thresholds in Healthy Adults: A Double-Blind, Sham-Controlled Study. Focus (American) Tj ETQq0 0 0 rgB	T/Ov erk ock	10 Tf 50 697
3	Novel Neurotherapeutics. Focus (American Psychiatric Publishing), 2022, 20, 1-2.	0.8	0
4	Noninvasive Delivery of Biologicals to the Brain. Focus (American Psychiatric Publishing), 2022, 20, 64-70.	0.8	0
5	Current State of Potential Mechanisms Supporting Low Intensity Focused Ultrasound for Neuromodulation. Frontiers in Human Neuroscience, 2022, 16, 872639.	2.0	23
6	Design, Development, and Operation of a Low-Intensity Focused Ultrasound Pulsation (LIFUP) System for Clinical Use. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2021, 68, 54-64.	3.0	17
7	Treatment of Dementia With Bosutinib. Neurology: Clinical Practice, 2021, 11, e294-e302.	1.6	10
8	Safety of focused ultrasound neuromodulation in humans with temporal lobe epilepsy. Brain Stimulation, 2021, 14, 1022-1031.	1.6	41
9	Brain circuitry underlying the ABC model of anxiety. Journal of Psychiatric Research, 2021, 138, 3-14.	3.1	11
10	Repetitive transcranial magnetic stimulation for smoking cessation: aÂpivotal multicenter doubleâ€blind randomized controlled trial. World Psychiatry, 2021, 20, 397-404.	10.4	97
11	Translating state-of-the-art brain magnetic resonance imaging (MRI) techniques into clinical practice: multimodal MRI differentiates dementia subtypes in a traditional clinical setting. Quantitative Imaging in Medicine and Surgery, 2021, 11, 4056-4073.	2.0	7
12	Histological examination of focused ultrasound effects on human brain tissue. Brain Stimulation, 2021, 14, 1486-1488.	1.6	3
13	A case of COVID-encephalopathy imaged with fMRI and treated with near infrared light. Brain Stimulation, 2021, 14, 1444-1446.	1.6	3
14	Reversible neuroinhibition does not require a thermal mechanism. Brain Stimulation, 2020, 13, 262.	1.6	6
15	Sonication of the anterior thalamus with MRI-Guided transcranial focused ultrasound (tFUS) alters pain thresholds in healthy adults: A double-blind, sham-controlled study. Brain Stimulation, 2020, 13, 1805-1812.	1.6	72
16	Focused transcranial ultrasound for treatment of neurodegenerative dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 374-381.	3.7	40
17	Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry, 2019, 176, 931-938.	7.2	250
18	Cultural influences on mental health symptoms in a primary care sample of Latinx patients. Journal of Anxiety Disorders, 2018, 55, 39-47.	3.2	33

#	Article	IF	CITATIONS
19	Age Differences in Death and Suicidal Ideation in Anxious Primary Care Patients. Clinical Gerontologist, 2018, 41, 271-281.	2.2	9
20	Improving Outcomes for Patients With Medication-Resistant Anxiety: Effects of Collaborative Care With Cognitive Behavioral Therapy. Focus (American Psychiatric Publishing), 2017, 15, 211-218.	0.8	0
21	Advancing Personalized Medicine: Application of a Novel Statistical Method to Identify Treatment Moderators in the Coordinated Anxiety Learning and Management Study. Behavior Therapy, 2017, 48, 490-500.	2.4	21
22	Non-Invasive Ultrasonic Thalamic Stimulation in Disorders of Consciousness after Severe Brain Injury: A First-in-Man Report. Brain Stimulation, 2016, 9, 940-941.	1.6	192
23	Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. Depression and Anxiety, 2016, 33, 1099-1106.	4.1	10
24	Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry, 2015, 14, 64-73.	10.4	293
25	The impact of alcohol use severity on anxiety treatment outcomes in a large effectiveness trial in primary care. Journal of Anxiety Disorders, 2015, 30, 88-93.	3.2	17
26	Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. Psychiatry Research, 2015, 229, 133-142.	3.3	9
27	A non-linear dynamical approach to belief revision in cognitive behavioral therapy. Frontiers in Computational Neuroscience, 2014, 8, 55.	2.1	7
28	Synergistic application of cardiac sympathetic decentralization and comprehensive psychiatric treatment in the management of anxiety and electrical storm. Frontiers in Integrative Neuroscience, 2014, 7, 98.	2.1	8
29	CHANGES IN SELF-EFFICACY AND OUTCOME EXPECTANCY AS PREDICTORS OF ANXIETY OUTCOMES FROM THE CALM STUDY. Depression and Anxiety, 2014, 31, 678-689.	4.1	69
30	PERCEIVED SOCIAL SUPPORT MEDIATES ANXIETY AND DEPRESSIVE SYMPTOM CHANGES FOLLOWING PRIMARY CARE INTERVENTION. Depression and Anxiety, 2014, 31, 436-442.	4.1	108
31	Stress and Anxiety. Psychiatric Clinics of North America, 2014, 37, 489-518.	1.3	29
32	Low-Intensity Focused Ultrasound Pulsation Device Used During Magnetic Resonance Imaging: Evaluation of Magnetic Resonance Imaging-Related Heating at 3 Tesla/128 MHz. Neuromodulation, 2014, 17, 236-241.	0.8	8
33	Interactions Between Diabetes and Anxiety and Depression. Endocrinology and Metabolism Clinics of North America, 2014, 43, 269-283.	3.2	31
34	Treatment engagement and response to CBT among Latinos with anxiety disorders in primary care Journal of Consulting and Clinical Psychology, 2014, 82, 392-403.	2.0	60
35	Suicidal ideation and risk factors in primary care patients with anxiety disorders. Psychiatry Research, 2013, 209, 60-65.	3.3	43
36	CBT COMPETENCE IN NOVICE THERAPISTS IMPROVES ANXIETY OUTCOMES. Depression and Anxiety, 2013, 30, 97-115.	4.1	26

#	Article	IF	CITATIONS
37	Anxiety treatment improves physical functioning with oblique scoring of the SF-12 Short Form Health Survey. General Hospital Psychiatry, 2013, 35, 291-296.	2.4	12
38	Effects of Medical Comorbidity on Anxiety Treatment Outcomes in Primary Care. Psychosomatic Medicine, 2013, 75, 713-720.	2.0	17
39	Age differences in treatment response to a collaborative care intervention for anxiety disorders. British Journal of Psychiatry, 2013, 203, 65-72.	2.8	51
40	Does a Quality Improvement Intervention for Anxiety Result in Differential Outcomes for Lower-Income Patients?. American Journal of Psychiatry, 2013, 170, 218-225.	7.2	9
41	Current diagnosis and treatment of anxiety disorders. P and T, 2013, 38, 30-57.	0.9	55
42	Use of Complementary and Alternative Medicine in a Large Sample of Anxiety Patients. Psychosomatics, 2012, 53, 266-272.	2.5	74
43	Effects of cranial electrotherapy stimulation on resting state brain activity. Brain and Behavior, 2012, 2, 211-220.	2.2	55
44	Abbreviated PTSD Checklist (PCL) as a guide to clinical response. General Hospital Psychiatry, 2012, 34, 332-338.	2.4	178
45	Effects of Co-Occurring Depression on Treatment for Anxiety Disorders. Journal of Clinical Psychiatry, 2012, 73, 1509-1516.	2.2	17
46	Focused ultrasound modulates region-specific brain activity. NeuroImage, 2011, 56, 1267-1275.	4.2	494
47	Quality of life and functional impairment in compulsive hoarding. Journal of Psychiatric Research, 2011, 45, 475-480.	3.1	75
48	Training primary care staff to deliver a computer-assisted cognitive–behavioral therapy program for anxiety disorders. General Hospital Psychiatry, 2011, 33, 336-342.	2.4	27
49	A review of low-intensity focused ultrasound pulsation. Brain Stimulation, 2011, 4, 125-136.	1.6	332
50	Focused ultrasound-mediated suppression of chemically-induced acute epileptic EEG activity. BMC Neuroscience, 2011, 12, 23.	1.9	226
51	Disorder-Specific Impact of Coordinated Anxiety Learning and Management Treatment for Anxiety Disorders in Primary Care. Archives of General Psychiatry, 2011, 68, 378.	12.3	113
52	Quality of and Patient Satisfaction With Primary Health Care for Anxiety Disorders. Journal of Clinical Psychiatry, 2011, 72, 970-976.	2.2	84
53	Clinical and subthreshold panic disorder. Depression and Anxiety, 2010, 27, 381-389.	4.1	48
54	Delivery of Evidence-Based Treatment for Multiple Anxiety Disorders in Primary Care. JAMA - Journal of the American Medical Association, 2010, 303, 1921.	7.4	364

#	Article	IF	CITATIONS
55	Impaired identity recognition of faces with emotional expressions in body dysmorphic disorder. Psychiatry Research, 2010, 179, 318-323.	3.3	36
56	Dynamical Principles of Emotion-Cognition Interaction: Mathematical Images of Mental Disorders. PLoS ONE, 2010, 5, e12547.	2.5	47
57	Brief Intervention for Anxiety in Primary Care Patients. Journal of the American Board of Family Medicine, 2009, 22, 175-186.	1.5	41
58	Regional brain volumes and symptom severity in body dysmorphic disorder. Psychiatry Research - Neuroimaging, 2009, 172, 161-167.	1.8	61
59	Validation of a brief measure of anxiety-related severity and impairment: The Overall Anxiety Severity and Impairment Scale (OASIS). Journal of Affective Disorders, 2009, 112, 92-101.	4.1	270
60	Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depression and Anxiety, 2009, 26, 235-242.	4.1	154
61	Treatment for anxiety disorders: Efficacy to effectiveness to implementation. Behaviour Research and Therapy, 2009, 47, 931-937.	3.1	83
62	Predictors of Clinical Improvement in a Randomized Effectiveness Trial for Primary Care Patients With Panic Disorder. Journal of Nervous and Mental Disease, 2009, 197, 715-721.	1.0	23
63	A Preliminary Study of fMRI-Guided rTMS in the Treatment of Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2009, 70, 431-432.	2.2	34
64	Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology Bulletin, 2009, 42, 81-93.	0.0	61
65	A Pilot Study of <i>Rhodiola rosea</i> (Rhodax [®]) for Generalized Anxiety Disorder (GAD). Journal of Alternative and Complementary Medicine, 2008, 14, 175-180.	2.1	82
66	The effect of attributional processes concerning medication taking on return of fear Journal of Consulting and Clinical Psychology, 2008, 76, 478-490.	2.0	62
67	A Pilot Study of Cranial Electrotherapy Stimulation for Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2008, 69, 412-417.	2.2	56
68	A Preliminary Study of fMRI-Guided rTMS in the Treatment of Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2008, 69, 1092-1098.	2.2	88
69	A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacology Bulletin, 2008, 41, 46-51.	0.0	25
70	Visual Information Processing of Faces in Body Dysmorphic Disorder. Archives of General Psychiatry, 2007, 64, 1417.	12.3	183
71	Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders. General Hospital Psychiatry, 2007, 29, 379-387.	2.4	99
72	CBT Intensity and Outcome for Panic Disorder in a Primary Care Setting. Behavior Therapy, 2006, 37, 112-119.	2.4	75

#	Article	IF	CITATIONS
73	Functional Impact and Health Utility of Anxiety Disorders in Primary Care Outpatients. Medical Care, 2005, 43, 1164-1170.	2.4	203
74	St John??s wort versus placebo in obsessive???compulsive disorder: results from a double-blind study. International Clinical Psychopharmacology, 2005, 20, 299-304.	1.7	70
75	Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders. General Hospital Psychiatry, 2005, 27, 313-318.	2.4	31
76	Beliefs about psychotropic medication and psychotherapy among primary care patients with anxiety disorders. Depression and Anxiety, 2005, 21, 99-105.	4.1	47
77	Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology, 2005, 177, 280-288.	3.1	95
78	Perceived Unmet Need for Mental Health Treatment and Barriers to Care Among Patients With Panic Disorder. Psychiatric Services, 2005, 56, 988-994.	2.0	59
79	Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?. Psychological Medicine, 2005, 35, 1645-1654.	4.5	37
80	A Randomized Effectiveness Trial of Cognitive-Behavioral Therapy and Medication for Primary Care Panic Disorder. Archives of General Psychiatry, 2005, 62, 290.	12.3	251
81	Use of Herbal Medicine in Primary Care Patients With Mood and Anxiety Disorders. Psychosomatics, 2005, 46, 117-122.	2.5	40
82	Quality of Care for Primary Care Patients With Anxiety Disorders. American Journal of Psychiatry, 2004, 161, 2230-2237.	7.2	187
83	Diagnosis and Treatment of Anxiety. Focus (American Psychiatric Publishing), 2004, 2, 333-342.	0.8	4
84	The Composite International Diagnostic Interview (CIDI-AUTO): problems and remedies for diagnosing panic disorder and social phobia. International Journal of Methods in Psychiatric Research, 2003, 12, 167-181.	2.1	17
85	Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients. Disease-a-Month, 2003, 49, 261-273.	1.1	0
86	Moving Treatment Research From Clinical Trials to the Real World. Psychiatric Services, 2003, 54, 327-332.	2.0	101
87	DOES NOCTURNAL PANIC REPRESENT A MORE SEVERE FORM OF PANIC DISORDER?. Journal of Nervous and Mental Disease, 2002, 190, 611-618.	1.0	48
88	Presleep attributions about arousal during sleep: Nocturnal panic Journal of Abnormal Psychology, 2002, 111, 53-62.	1.9	32
89	Treating panic disorder in primary care: a collaborative care intervention. General Hospital Psychiatry, 2002, 24, 148-155.	2.4	43
90	Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients. General Hospital Psychiatry, 2002, 24, 316-321.	2.4	60

#	Article	IF	CITATIONS
91	Obsessive-Compulsive Hoarding. Journal of Clinical Psychiatry, 2002, 63, 21-27.	2.2	163
92	Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. Journal of Clinical Psychiatry, 2002, 63, 21-7.	2.2	77
93	Functional MRI changes during panic anticipation and imagery exposure. NeuroReport, 2001, 12, 3953-3957.	1.2	156
94	Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders. Depression and Anxiety, 2001, 14, 214-218.	4.1	128
95	Autonomic reactivity of panic patients during a CO2 inhalation procedure. , 2000, 11, 15-26.		50
96	Side Effects and Time Course of Response in a Placebo-Controlled Trial of Fluoxetine for the Treatment of Geriatric Depression. Journal of Clinical Psychopharmacology, 2000, 20, 658-665.	1.4	17
97	Pilot open-label study of nefazodone in panic disorder. Depression and Anxiety, 1999, 10, 137-139.	4.1	23
98	Development of a Brief Diagnostic Screen for Panic Disorder in Primary Care. Psychosomatic Medicine, 1999, 61, 359-364.	2.0	84
99	Quality-of-Life Changes Among Patients With Obsessive-Compulsive Disorder in a Partial Hospitalization Program. Psychiatric Services, 1999, 50, 412-414.	2.0	55
100	Side Effects as Predictors of Drug Response in Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 1999, 19, 459-465.	1.4	28
101	Panic Disorder in the Primary Care Setting. Journal of Clinical Psychiatry, 1999, 60, 492-499.	2.2	140
102	Clinical Characteristics of Response to Fluoxetine Treatment of Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 1998, 18, 185-192.	1.4	56
103	Four-dimensional anxiety and depression scale: A preliminary psychometric report. Anxiety, 1996, 2, 47-50.	0.4	7
104	Impact of Physical Illness on Quality of Life and Antidepressant Response in Geriatric Major Depression. Journal of the American Geriatrics Society, 1996, 44, 1220-1225.	2.6	56
105	SITE VARIABILITY IN A MULTISITE GERIATRIC DEPRESSION TRIAL. International Journal of Geriatric Psychiatry, 1996, 11, 1089-1095.	2.7	14
106	Relationship Between Early Side Effects and Therapeutic Effects of Clomipramine Therapy in Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 1996, 16, 324-328.	1.4	12
107	Clinical Response Predictors in a Double-Blind, Placebo-Controlled Trial of Fluoxetine for Geriatric Major Depression. International Psychogeriatrics, 1995, 7, 41-53.	1.0	33
108	Screening for anxiety disorders in the primary care setting. Family Practice, 1995, 12, 448-451.	1.9	13

ALEXANDER BYSTRITSKY

#	Article	IF	CITATIONS
109	Brief cognitive-behavioral versus nondirective therapy for panic disorder. Journal of Behavior Therapy and Experimental Psychiatry, 1995, 26, 113-120.	1.2	96
110	Ambulatory monitoring of panic patients during regular activity: A preliminary report. Biological Psychiatry, 1995, 38, 684-689.	1.3	20
111	Etiological beliefs and treatment preferences in anxietyâ€disordered patients. Anxiety, 1994, 1, 134-137.	0.4	6
112	Doubleâ€blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety, 1994, 1, 287-290.	0.4	23
113	Predictors of Treatment Response in Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 1994, 14, 247???254.	1.4	81
114	Inert Placebo Versus Active Medication. Journal of Nervous and Mental Disease, 1994, 182, 485-487.	1.0	26
115	Psychometric Discrimination between Anxiety and Depression. Journal of Nervous and Mental Disease, 1993, 181, 265-267.	1.0	6
116	Continuous physiological changes and subjective reports in panic patients: A preliminary methodological report. Biological Psychiatry, 1992, 32, 766-777.	1.3	39
117	Low Dose Desipramine Treatment of Cocaine-Related Panic Attacks. Journal of Nervous and Mental Disease, 1991, 179, 755-758.	1.0	14
118	Development of a multidimensional scale of anxiety. Journal of Anxiety Disorders, 1990, 4, 99-115.	3.2	32